NRx Pharmaceuticals (NASDAQ: NRXP) Announces Last Patient,

New Post Public Reply Private Reply Replies (0) Message Board
Lee Adams
213
NRx Pharmaceuticals (NASDAQ: NRXP) Announces Last Patient, Last Visit in its Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression

Marks a major step in the development of what could be the first drug approved for Suicidal Bipolar Depression

The study database is being cleaned and locked; statistical analysis and top-line data to follow shortly thereafter

Study maintained 95% concordance rate between study sites and central raters on primary endpoint. No unexpected Serious Adverse Events were reported.

Positive data and FDA comment would trigger the next $4 million milestone payment from partners Alvogen and Lotus and their assumption of development costs; agreement provides for up to $329 million in milestone payments and a royalty on Net Sales in the mid-teens

RADNOR, Pa., March 4, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company" , a clinical-stage biopharmaceutical company, today announced that the 74th and last evaluable patient has completed their day 42 visit in its Phase 2b/3 study of NRX-101, the Company's patented combination of the NMDA antagonist D-cycloserine and lurasidone, in Suicidal Treatment Resistant Bipolar Depression. The database is being cleaned, finalized, and locked; statistical analysis will then be performed, with top-line data to follow shortly thereafter. As previously disclosed, positive data from this trial triggers a milestone payment from Alvogen. Alvogen will then be responsible for further development and commercialization costs for this program.


NRX-101 has been awarded Breakthrough Therapy Designation, Fast Track Designation, a Biomarker Letter of Support, and a Special Protocol Agreement by the FDA for treatment of suicidal bipolar depression. It is the only oral medication to have demonstrated reduced suicidal ideation in patients with bipolar depression, a lethal disease that claims the lives of one in five who live with it.

"This is the first clinical trial, to the company's knowledge, conducted among patients with suicidal bipolar depression in the outpatient setting. Our previous trial measured the ability of NRX-101 to maintain the anti-depressant and anti-suicidal effect of ketamine administered in the hospital setting. These patients, whose clinical need is urgent and extraordinary have routinely been excluded from the clinical trials of all previously-known anti-depressant drugs. said Dr. Jonathan Javitt, Founder, Chairman and Chief Scientist of NRx Pharmaceuticals. Although there were patients whose depression worsened and required hospitalization (we don't yet know whether they were on NRX-101 or comparator), patient safety was maintained, and no trial participant suffered a serious unexpected adverse outcome. Our thanks go out to our investigators, clinics, partners and, most importantly, our amazing patients and their families for seeing this study through to this important milestone," "

The Phase 2b/3 trial (www.clinicaltrials.gov NCT 03395392) is a randomized, prospective, multicenter, double-blind study comparing NRX-101 to lurasidone over six weeks. The Principal Investigator is Prof. Andrew Nierenberg of Harvard Massachusetts General Hospital. The primary efficacy endpoint is reduction in depression as measured on the MADRS scale and the secondary endpoint is reduction of suicidal ideation as measured by the Clinical Global Impression Suicidality Scale (CGI-SS). As previously disclosed, treatment compliance and concordance of local raters to central raters scores was in excess of 94%, well above the industry standard that is normally seen in CNS trials.

Top-line results are expected around the end of this quarter.

About NRx Pharmaceuticals

NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx has partnered with Alvogen and Lotus around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.

NRx has recently announced plans to submit a New Drug Application for HTX-100 (IV ketamine), through Hope Therapeutics, in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.

About HOPE Therapeutics, Inc.

HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a Specialty Pharmaceutical Company, wholly-owned by NRX Pharmaceuticals focused on development and marketing of an FDA-approved form of intravenous ketamine for the treatment of acute suicidality and depression together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.

Notice Regarding Forward-Looking Statements

The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the proposed public offering and the timing and the use of the proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.


https://c212.net/c/img/favicon.png?sn=CL51263...2024-03-04 View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-nasdaq-nrxp-announces-last-patient-last-visit-in-its-phase-2b3-trial-of-nrx-101-in-suicidal-treatment-resistant-bipolar-depression-302078041.html

SOURCE NRx Pharmaceuticals, Inc.

NRx Pharmaceuticals Inc. (NRXP) Stock Research Links

NRXP Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Workers Are Burning Savings as Pay Falls Behind Costs

Updated Category News Views 47

Payroll optimism has been ground into dust by the ordinary bills nobody can dodge. Monster's 2026 Cost of Living Report says 93% of employed U.S. workers feel their wages are failing to keep up with costs, barely different from 95% in both 2024 and 2025. That is not a blip, and it is not workers merely grousing about prices. Three years of nearly identical frustration...

Continue Reading
Cedars-Sinai and nference Build a Living Data Engine

Updated Category News Views 151

Five million patient histories are not a flashy product demo. They are a serious raw-material advantage, provided the data can be protected, organized, and made useful without turning clinical research into a carnival of loose claims. That is the real weight behind nference's long-term collaboration with Cedars-Sinai, announced November 20, 2026. The pair plan to build a...

Continue Reading
Northgate’s Stanton Opening Puts Community Work First

Updated Category News Views 75

A 55,721-square-foot grocery opening can look like ordinary retail churn until you notice where the money and attention are landing. Northgate González Market’s new Stanton location arrives ahead of Thanksgiving, yes, but the more telling detail is the company’s decision to pair a major store launch with 375 jobs and more than $30,000 directed toward families,...

Continue Reading
RingConn Bets Middle-earth Fandom Can Boost Health Wearables

Updated Category News Views 102

A Familiar Gold Band Meets a Crowded Wearables Market RingConn has taken one of pop culture's most loaded objects and turned it into a health-tracking accessory, which is either clever brand work or a costly bit of cosplay depending on execution. The company unveiled The One Ring, a limited-edition version of its Gen 3 Smart Ring, through a partnership with Warner Bros....

Continue Reading
Anduin Opens Its Investor Portal Beyond Early Users

Updated Category News Views 68

Private-market paperwork has long been a swamp of portals, PDFs, email chains, and somebody chasing down a wire change at the worst possible moment. Anduin is taking a swing at that mess by opening its Investor Portal to all customers after building it with leading asset managers and operating it with their investors. The pitch is sensible: give limited partners one...

Continue Reading
Rosenblatt Book Puts Vegas Casino Blind Spots on Display

Updated Category News Views 143

A locked casino floor is supposed to make secrets expensive. That is why the pitch behind ROSENBLATT lands with a little more weight than the usual Vegas chest-thumping: the coming memoir says Darryl Rosenblatt became a million-dollar gambler while using none of his own money, and that casino operators did not grasp the full shape of what had happened for years. Take a...

Continue Reading
NTN Data Breach Raises Hard Questions Beyond Lawsuit

Updated Category News Views 124

Paperwork lifted from a factory network can become a very expensive loose bolt. NTN Bearing Corporation of America, a U.S. maker of bearings and automotive components, has reported a data-security incident that may have exposed sensitive information belonging to current and former employees. A law firm, Edelson Lechtzin LLP, is investigating potential class-action claims....

Continue Reading
CVS Puts Youth Soccer Stories on Its Store Shelves

Updated Category News Views 60

Two kids with real community ties just got a megaphone most grown-ups never receive. CVS Pharmacy has named Caroline, 9, of Holmes Beach, Florida, and Zoe, 12, of Los Angeles, as the first grand-prize winners of its Home Team Heroes youth soccer contest. Each player’s selected nonprofit soccer organization will receive a $25,000 grant, while their stories will appear on...

Continue Reading
Digital Diabetes Care Has a Bigger Prize Than Devices

Updated Category News Views 121

A glucose sensor is becoming less a gadget than a running conversation between patient, clinician and software. That shift matters because diabetes management is leaving the occasional clinic visit and moving into daily life, where the useful product is not merely a reading but a pattern someone can act on. The sector deserves attention from investors, but it also...

Continue Reading
Midterm Voters Put Cost Relief Ahead of Washington Wars

Updated Category News Views 78

Gas pumps and medical bills have a way of humiliating every grand political slogan ever printed. Seven Letter Insight's latest post-election survey says confirmed 2026 midterm voters want the 120th Congress to deal with costs first, particularly gas prices, health care, restoring health care tax credits and energy bills. That is not a glamorous mandate. It is, however,...

Continue Reading

Top 5 Most Recently Viewed Articles

Yonder Media Mobile Takes Legal Action Against FuboTV

Updated Category News Views 146

Yonder Media Mobile Initiates Lawsuit Against FuboTV In a recent announcement, Yonder Media Mobile Inc. ("YMM") has taken significant legal action against FuboTV, Inc. ("FuboTV"). This lawsuit contends that FuboTV has engaged in deceptive practices, causing substantial harm to YMM over an extended period. Serious Allegations of Misconduct The heart of the lawsuit revolves...

Continue Reading
United Airlines Stock Dive: It's Crazy but Predictable

Updated Category News Views 243

What's Happening With United Airlines Stock? So, here's the scoop: United Airlines Holdings, Inc. (NASDAQ:UAL) is trying to claw back into the green after a rough patch, you know? Just yesterday, it took a dive—down almost 6%—all thanks to those pesky rising fuel costs. Crude oil prices are hitting six-month highs again, and yeah, that's got investors sweating over...

Continue Reading
Fingerprint Cards' Management Boosts Confidence with New Investments

Updated Category News Views 136

Management's Bold Move in the Rights Issue Fingerprint Cards AB (publ) has taken a significant step in demonstrating their confidence in the company’s future. The CEO and CFO have decided to invest an impressive SEK 2 million in the ongoing rights issue without utilizing unit rights. This decision coincides with the company's efforts to raise approximately SEK 159.9...

Continue Reading
Investigation Launched for Aehr Test Systems, Inc. Investors

Updated Category News Views 200

Investigation for Aehr Test Systems, Inc. Investors Glancy Prongay & Murray LLP, a prominent national law firm specializing in shareholder rights, has officially commenced an investigation into Aehr Test Systems, Inc. (NASDAQ: AEHR) on behalf of investors. This initiative aims to scrutinize potential violations of federal securities laws by the company. Why the...

Continue Reading
Exciting Dual Reward Campaign by AB DAO and Bitget Unveiled

Updated Category News Views 180

AB DAO and Bitget Join Forces for a Rewarding Initiative AB DAO is thrilled to reveal its newest collaboration with Bitget, a prominent name in the digital asset trading sphere. This partnership has led to the creation of a dual reward campaign, aimed at boosting user engagement and enhancing the overall ecosystem. The campaign will distribute a staggering total of...

Continue Reading